Research Projects

Age related memory decline, mild cognitive impairments (MCI), and cognitive impairments that occur with diseases, such as stroke, brain injuries, or early stages of dementia, have negative effects on the ability to navigate and to orient. Affected people who repeatedly start experiencing disorientation events often become scared of venturing out...

Alzheimer’s disease (AD) has far-reaching societal and economic consequences, emphasizing the urgent need for effective treatment solutions. However, to date, over 99% of AD clinical trials have failed. Inadequate patient stratification is a key contributing factor due to the enormous clinical and pathological heterogeneity in AD. AD is...

The MEMOLOAD project will focus on the molecular and biological mechanisms underlying memory loss that occurs in Alzheimer’s disease, the leading cause of dementia and an enormous medical, social and economic challenge to Europe. Several lines of evidence point to accumulation of beta-amyloid peptide (Aß) in the brain as the key pathologic event in...

Alzheimer’s disease (AD) and Parkinson’s disease (PD) are common in elderly and the prevalence of these is increasing. AD and PD have distinct pathogenesis, which precede the overt clinical symptoms by 10-15 years, opening a window for early diagnosis and treatment. New disease-modifying therapies are likely to be most efficient if initiated before...

The blood-brain barrier (BBB) is a major obstacle in treating diseases of the central nervous system (CNS) such as Parkinson's, Alzheimer's, Schizophrenia and brain cancer, affecting 180 million Europeans with less than 5% of current candidate drugs effectively reaching the brain. NAP4DIVE strives to revolutionize the traditionally expensive and...

Spider silk is Nature’s high performance material that has the potential to revolutionize the materials industry. However, production and spinning of artificial spider silk fibers are challenging, and current methods to produce silk fibers include denaturing conditions which prevent the silk proteins from assembling into fibers in the same complex...

Alzheimers disease (AD) is the most common cause of dementia and a major global health challenge. AD has a long pre-symptomatic phase spanning several decades. The accuracy of clinical AD diagnostics is mediocre, especially in primary care. This results in suboptimal treatment and care, which is especially problematic in light of emerging anti...

The objective of this project is to develop a business plan for the continued clinical development and commercialisation of ALZ-101 – a novel therapeutic Alzheimer´s disease (AD) vaccine candidate designed to prevent neurodegeneration in the brain. AD is a therapeutic area in dire need of effective treatments. The disease, which primarily afflicts...

Alzheimer’s disease (AD) heterogeneity is associated with distinct risk factors, clinical manifestations, rates of cognitive decline, and comorbidities. However, this population variance is not properly incorporated in clinical trial design, directly hampering successful development of treatments. As the field is shifting towards (early) secondary...

A major challenge facing Europe is its ageing population and associated increase in diagnosed cases of neurodegenerative diseases (NDD). Parkinson’s disease (PD) is associated with tremor and loss of motor functions due to progressive degeneration of dopaminergic neurons in the brain. This can lead to memory loss and dementia, which is associated...

Neurodegenerative disorders, including Alzheimer’s disease, Parkinson’s disease, frontotemporal dementias and prion diseases affect ~50 million people worldwide. Alzheimer’s disease, the most prevalent form, affects ~6% of the population over 65 years of age and is one of the leading causes of death in the elderly. All these diseases have...

Critical to our understanding of Alzheimer’s disease (AD) and also to finding therapies is determining how key pathological factors interact and relate to neuronal toxicity, symptoms and disease progression. My research has focussed on amyloid beta (Aβ) moities and demonstrated that cerebrospinal fluid (CSF) Aβ42 correlates with cerebral Aβ...